


What is claimed is:

1. A compound according to Formula (1):



5 wherein:

X is selected from the group consisting of CH_2NR_2 , O, NR_2CO , CONR_2 and a bond;

Y represents O, CH_2 or a bond;

Z represents H or F;

10 R is selected from the group consisting of:

C_{2-6} alkyl optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; C_{2-6} alkenyl optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; C_{2-6} alkynyl optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; $(\text{CH}_2)_n-\text{C}_{3-6}$ carbocycle optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl; $(\text{CH}_2)_n-\text{R}_3$ {where R_3 is phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole; R_3 is optionally substituted by one or more Cl, Br, I, C_{1-3} alkyl optionally substituted by one to three F, or C_{1-2} alkoxy, optionally substituted by one to three F};

15 20 R1 is selected from the group consisting of:

hydrogen, C_{1-3} substituted alkyl, C_{2-3} substituted alkenyl, C_{2-3} substituted alkynyl, $(\text{CH}_2)_n-\text{C}_{3-6}$ substituted carbocycle, aryl, heteraryl, heterocyclic, and aminocarbonyl provided that X is $(\text{CH}_2)_n$ when R_1 represents aminocarbonyl;

R2 represents:


25 hydrogen, or C_{1-3} substituted alkyl,;

X represents $(\text{CH}_2)_n$, NR_2 , O, NR_2CO , CONR_2 or a bond;

Y represents O, CH_2 or a covalent bond;

Z represents hydrogen or fluorine; preferably fluoroine; and n represents an integer between 0 and 2 or a salt, solvate, or physiologically functional derivative thereof.

2. A compound as claimed in claim 1, with the following absolute configuration:



5

wherein:

X is selected from the group consisting of CH_2 , NR_2 , O, NR_2CO , CONR_2 and a bond;

Y represents O, CH_2 or a bond;

- 10 Z represents H or F;

3. A compound as claimed in claim 1, wherein X = CH_2 or a bond; or a salt, solvate, or physiologically functional derivative thereof.

- 15 4. A compound as claimed in claim 1, wherein X = NR_2 ; or a salt, solvate, or physiologically functional derivative thereof.

5. A compound according to claim 3 selected from the group consisting of:

N-[(R)-2-(5-Benzyl-[1,3]dioxol-5-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

- 20 N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

N-Hydroxy-N-{(R)-2-[5-(7-methoxy-benzofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydroquinolin-6-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

- 25 N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydro-quinolin-8-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-[(R)-2-(5-pyridin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-

- formamide;
- N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;
- N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-
5 formamide;
- N-Hydroxy-N-{(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- N-Hydroxy-N-{(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- 10 N-{(R)-2-[5-(2,3-Dichloro-phenoxyethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy formamide;
- N-Hydroxy-N-{(R)-2-[5-(4-methoxy-phenoxyethyl)-[1,3,4]oxadiazol-2-yl]-heptyl} -formamide;
- N-((R)-2-[5-[4-(4-Acetyl-piperazin-1-yl)-phenoxyethyl]-[1,3,4]oxadiazol-2-yl]-
15 heptyl)-N-hydroxy-formamide;
- N-Hydroxy-N-{(R)-2-[5-(1-methyl-1H-pyrrol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- N-Hydroxy-N-[(R)-2-(5-pyridin-2-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- 20 N-Hydroxy-N-[(R)-2-(5-pyridin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- N-Hydroxy-N-{(R)-2-[5-(2,6-dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl} formamide;
- N-Hydroxy-N-{(R)-2-[5-(1H-indol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-
25 formamide;
- N-{(R)-2-[(S)-5-(2,3-Dihydro-benzo[1,4]dioxin-2-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;
- N-[(R)-2-(5-Benzofuran-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy-
formamide;
- 30 N-Hydroxy-N-[(R)-2-(5-pyrimidin-2-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- N-{(R)-2-[5-(2,3-Dihydro-benzo[d]isoxazol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-

- heptyl}-N-hydroxy-formamide;
- N-Hydroxy-N-[(R)-2-(5-phenoxyethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- N-Hydroxy-N-{(R)-2-[(S)-5-(1,2,3,4-tetrahydro-isoquinolin-3-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- 5 N-Hydroxy-N-{(R)-2-[5-(4-imidazol-1-yl-phenoxyethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- N-Hydroxy-N-{(R)-2-[5-(quinolin-6-yloxyethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- 10 5-{(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazole-2-carboxylic acid phenylamide;
- N-Hydroxy-N-[(R)-2-(5-phenylaminomethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- N-{(R)-2-[5-(2-Chloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-Hydroxy-formamide;
- 15 N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclohexyl-propyl]-N-hydroxyformamide.
- N-((R)-2-{5-[2-(1H-Benzoimidazol-2-yl)-ethyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-N-Hydroxy-formamide;
- N-Hydroxy-N-{(R)-2-[5-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- 20 N-Hydroxy-N-{(R)-2-[5-(3-methyl-isoxazol-5-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- N-Hydroxy-N-{(R)-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
- N-Hydroxy-N-(2-{5-[(4-trifluoromethyl-pyrimidin-2-ylamino)-methyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-formamide;
- 25 N-{(R)-2-[5-(1H-Benzoimidazol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;
- N-Hydroxy-N-[(R)-2-(5-morpholin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- 30 N-Hydroxy-N-((R)-2-{5-[(3-trifluoromethyl-phenylamino)-methyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-formamide;

N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclopentyl-propyl]-N-hydroxyformamide;
N-Hydroxy-N-[(R)-2-(5-methyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide; and
N-Hydroxy-N-((R)-2-{5-[2-(1H-indol-3-yl)-ethyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-
formamide.

5

6. A compound according to claim 5 selected from the group consisting of:

N-Hydroxy--[(R)-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
N-(5-{(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazol-2-yl)-
10 benzamide;
N-{(R)-2-[5-(Chloro-trifluoromethyl-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-
hydroxy-formamide;
N-Hydroxy-N-{(R)-2-[5-(methyl-phenyl-amino)-[1,3,4]oxadiazol-2-yl]-heptyl}-
formamide;

15 Benzo[1,3]dioxole-5-carboxylic acid (5-{(R)-1-[(formyl-hydroxy-amino)-methyl]-
hexyl}-[1,3,4]oxadiazol-1,2-yl)-amide;
N-{(R)-2-[5-(3,5-Dichloro-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy
formamide;
N-[(S)-2-Fluoro-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy
20 formamide; and
N-{(R)-2-[5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-
N-hydroxy-formamide.

25 7. A method of treating a bacterial infection by administering to a subject in need
of treatment a compound according to claim 1.